Advertisement

Topics

Multi-marker Approach for Risk Assessment in PAH

2019-05-21 20:22:17 | BioPortfolio

Published on BioPortfolio: 2019-05-21T20:22:17-0400

Clinical Trials [2852 Associated Clinical Trials listed on BioPortfolio]

The Early Recognition of Pulmonary Arterial Hypertension

The early detection of pulmonary arterial hypertension may help to improve prognosis of the disease. It is assumed that in the early stages of pulmonary arterial hypertension, pulmonary ar...

Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension

Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension. The hyper...

Early Therapy of Pulmonary Arterial Hypertension

Exercise-induced increase of the pulmonary arterial pressure may be an early sign of pulmonary arterial hypertension. It has been shown that patients with normal pulmonary arterial pressur...

Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension

To assess the correlation between pulmonary IV-OCT and pulmonary IV-US measurements and standard PAH clinical measures of disease progression and the relative sensitivity of the techniques...

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

The purpose of this study to see how much study drug is in the blood after dosing children with pulmonary arterial hypertension (PAH) and to establish the correct dose for further clinical...

PubMed Articles [5087 Associated PubMed Articles listed on BioPortfolio]

Pulmonary arterial input impedance reflects the mechanical properties of pulmonary arterial remodeling in rats with pulmonary hypertension.

Although pulmonary arterial remolding in pulmonary hypertension (PH) changes the mechanical properties of the pulmonary artery, most clinical studies have focused on static mechanical properties (resi...

miR-27a promotes endothelial-mesenchymal transition in hypoxia-induced pulmonary arterial hypertension by suppressing BMP signaling.

Growing evidence suggests that endothelial-mesenchymal transition (EndMT) play key roles in pulmonary arterial remodeling during pulmonary arterial hypertension (PAH), but the underlying mechanisms ha...

Detection of Pediatric Pulmonary Arterial Hypertension by School Electrocardiography Mass Screening.

To detect pulmonary arterial hypertension (PAH) at any early stages is a promising approach to optimize the outcome.

Echocardiographic assessment of pulmonary arterial stiffness in human immunodeficiency virus-infected patients.

Pulmonary hypertension (PH) is one of the complications of human immunodeficiency virus (HIV) infection. Despite the emergence of effective therapies, pulmonary arterial hypertension is commonly seen,...

Pulmonary edema following initiation of a parenteral prostacyclin therapy for pulmonary arterial hypertension: a retrospective study.

Pulmonary edema may complicate the use of pulmonary arterial hypertension (PAH) targeted therapies. We aimed to determine the proportion of patients who develop pulmonary edema after initiation of par...

Medical and Biotech [MESH] Definitions

A malformation of the heart in which the embryonic common PULMONARY VEIN was not incorporated into the LEFT ATRIUM leaving behind a perforated fibromuscular membrane bisecting the left atrium, a three-atrium heart. The opening between the two left atrium sections determines the degree of obstruction to pulmonary venous return, pulmonary venous and pulmonary arterial hypertension.

A syndrome characterized by the clinical triad of advanced chronic liver disease, pulmonary vascular dilatations, and reduced arterial oxygenation (HYPOXEMIA) in the absence of intrinsic cardiopulmonary disease. This syndrome is common in the patients with LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL).

Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM.

Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.

A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).

More From BioPortfolio on "Multi-marker Approach for Risk Assessment in PAH"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial